Login to Your Account

A Tumor-Killing Cytokine Pays Off

GenVec's Flagship AntiCancer Drug, TNFerade, Performs Well In Both Preclinical, Clinical Trials

By David N. Leff

Wednesday, August 14, 2002
No Abstract

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription